VYNE Therapeutics (VYNE) Competitor Comparison
We are evaluating the key criteria listed to compare VYNE Therapeutics (VYNE) against its competitors in the Biotechnology industry.
Market Capitalization
311 / 368Gross Profits
135 / 278Total Revenue
258 / 300EBITDA
111 / 337Free Cashflow
89 / 352Quick Ratio
276 / 357Earnings per Share
14 / 359Dividend yield
0 / 6Total Cash
309 / 358Performance 3 years
278 / 368Performance 5 years
356 / 368Performance 10 years
347 / 368Linearity 3 years
278 / 368Linearity 5 years
299 / 368Linearity 10 years
312 / 368Total Rank
65 / 368Dividend Rank
310 / 368Valuation Rank
243 / 368Piotroski Rank
172 / 368Muliplier Rank
89 / 368Free Cashflow - VYNE ranking 89 / 352
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.